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Warburg effectColorectal neoplasia differentially expressed (CRNDE) is a novel gene that is activated early in colorectal cancer but
whose regulation and functions are unknown. CRNDE transcripts are recognized as long non-coding RNAs
(lncRNAs), which potentially interact with chromatin-modifying complexes to regulate gene expression via
epigenetic changes. Complex alternative splicing results in numerous transcripts from this gene, and we have
identiﬁed novel transcripts containing a highly-conserved sequence within intron 4 (“gVC-In4”). In colorectal
cancer cells, we demonstrate that treatment with insulin and insulin-like growth factors (IGF) repressed
CRNDE nuclear transcripts, including those encompassing gVC-In4. These repressive effects were negated by
use of inhibitors against either the PI3K/Akt/mTOR pathway or Raf/MAPK pathway, suggesting CRNDE is a
downstream target of both signaling cascades. Expression array analyses revealed that siRNA-mediated knock-
down of gVC-In4 transcripts affected the expression of many genes, which showed correlation with insulin/IGF
signaling pathway components and responses, including glucose and lipid metabolism. Some of the genes are
identical to those affected by insulin treatment in the same cell line. The results suggest that CRNDE expression
promotes the metabolic changes by which cancer cells switch to aerobic glycolysis (Warburg effect). This is the
ﬁrst report of a lncRNA regulated by insulin/IGFs, and ourﬁndings indicate a role for CRNDEnuclear transcripts in
regulating cellular metabolism which may correlate with their upregulation in colorectal cancer.
Crown Copyright © 2013 Published by Elsevier B.V. Open access under CC BY-NC-ND license.1. Introduction
CRNDEwas originally discovered as an upregulated gene in colorec-
tal adenomas and cancers, whereas it shows little to no expression in
normal colon epithelium [1]. In addition to CRC, CRNDE overexpression
has been observed in many other cancers, including gliomas in which it
is the most upregulated lncRNA [2,3]. CRNDE is a long non-coding RNA
(lncRNA), deﬁned as a class of non-protein coding transcripts over 200ially expressed; CRC, Colorectal
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lin-like growth factor 2; PI3K,
vated protein kinase; mTOR,
rowth factor 1 receptor; INSR,
y Pathway Analysis
e, NSW 2113 Australia, PO Box
0.
gmail.com (B.C. Ellis),
.au (P.L. Molloy).
r B.V. Open access under CC BY-NC-ND licenucleotides long; there is now abundant evidence for lncRNA roles in
critical cellular processes, especially transcriptional and epigenetic reg-
ulation. Khalil et al. demonstrated CRNDE (referred to as “lincIRX5”) to
be a lncRNA that interacts with chromatin-modifying complexes and
showed that the genes it regulated overlapped signiﬁcantly with those
controlled by polycomb repressive complex 2 (PRC2), which down-
regulates transcription via its histone methyltransferase activity [4].
Work by the same group in murine embryonic stem cells highlighted
themouse CRNDE ortholog (referred to as “linc1399”) as a lncRNA nec-
essary for maintenance of pluripotency [3,5]. CRNDE appears to play a
role in early development, and its expression is altered upon differenti-
ation of stem cells and various types of progenitor cells [1,3]. All such
evidence suggests that CRNDE acts through epigenetic mechanisms to
regulate cell differentiation/pluripotency, whichmay relate to its dereg-
ulation in cancer. However, the function of this lncRNA and the mecha-
nisms behind its upregulation in cancer are largely unknown.
Transcripts from the CRNDE locus undergo extensive alternative
splicing to generate a number of isoforms, which we have classiﬁed as
those fully spliced of introns (i.e. containing only exonic sequence) ver-
sus those that have retained intronic sequence [1]. Intron retention
tends to occur at the 3′ end of transcripts, likely a result of inefﬁcient
3′ splicing, a phenomenon more common in lncRNAs than in mRNAs
[6]. We have identiﬁed novel CRNDE transcripts; most noteworthy are
those that include a very highly conserved segment, which we havense.
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have found that transcripts containing intronic sequence localize in the
nucleus, while those completely lacking intronic sequences (i.e., exon-
only transcripts) are enriched in the cytoplasm [7]. The ﬁnding that
intronic RNA sequences retained in lncRNAs commonly bind the PRC2
subunit, EZH2, to repress target gene transcription supports a lncRNA
role for the nuclear, intron-retaining transcripts of CRNDE [8].
Khalil et al. (2009) performed knockdown of CRNDE in human ﬁbro-
blasts using siRNAs targeting the exonic sequences [4]. As detailed
below in Results, our analysis of the genes that were affected in the
knockdown cells suggests an association of CRNDE with insulin/IGF
signaling pathways. IGFs and insulin can operate through similarmech-
anisms to achieve downstream effects on cellular energy metabolism
(e.g. glucose uptake) and on oncogenic processes (e.g. increased prolif-
eration, translation, and cell survival) [9,10]. The traditional view is that
the metabolic impacts of insulin are primarily achieved through the
INSR, while IGFs promote mitogenic effects through the IGF1R. Yet,
there is crosstalk between the ligands and receptors, and evidence indi-
cates that insulin and IGFs can induce similar effects onmetabolism and
growth [11–14]. Upon ligand binding, INSR and IGF1R are activated
through tyrosine kinase-mediated autophosphorylation, thereby stimu-
lating various downstream pathways, the two best-characterized being
the PI3K/Akt/mTOR and the mitogen-activated protein kinase (MAPK)
pathways, the latter of which involves Ras, Raf, MEK, and ERK signaling
molecules.
Through these pathways, one effect of insulin/IGFs is to promote
cellular uptake of glucose, which is then catabolized via glycolysis and
oxidative metabolism, the latter providing the most efﬁcient mode of
ATP production [15]. Highly-proliferating tumor cells display an altered,
highly glycolytic metabolism called the Warburg effect [15,16]. Also
known as aerobic glycolysis, the Warburg effect is characterized by
increased rates of glycolysis but virtually no oxidative metabolism,
instead generating lactate from glucose breakdown. Likely related to
this, a hallmark of CRC cell metabolism is the switch in primary energy
source from butyrate to glucose, resulting in a glycolytic phenotype. An-
other feature of CRC is the frequent occurrence of activating mutations
within the PIK3CA and KRAS/BRAF genes (whose proteins act down-
stream of IGF1R and INSR) or deletion of PTEN (an inhibitor of PI3K
pathway signaling). Such changes have been linked to metabolic
reprogramming within cancer cells that is a characteristic of the
Warburg effect [17]. Consequently, altered expression of insulin signal-
ing and glucosemetabolism genesmight be expected in CRC. In fact, one
study reported signiﬁcant differences in themethylation and expression
proﬁles of such metabolic genes in normal colon mucosa of healthy
versus CRC patients [18]. Evidence for lncRNAs as mediators of these
methylation/transcriptional changes has not yet been suggested and,
to our knowledge, there is no existing documentation of lncRNAs
responsive to insulin/IGFs.
We investigated the effects of insulin/IGF on CRNDE expression and
report here the ﬁrst example of a lncRNA regulated by insulin and IGF1/
2 and, speciﬁcally, by their canonical downstream signaling cascades,
the PI3K/Akt/mTOR and Raf/MAPK pathways. Furthermore, siRNA-
mediated knockdown of the intronic gVC-In4 region within CRNDE
transcripts in CRC cells affected the expression of insulin/IGF-related
pathway genes, in a pattern suggestive of the Warburg effect. We pro-
pose that CRNDE's upregulation in CRC affects genes involved in glucose
and lipidmetabolism in amanner that aids the development of a cancer
phenotype.
2. Materials and methods
2.1. Cell culture
Human colorectal cancer cell lines, HCT116, HT29, and LS174T,
(from ATCC) were cultured inMcCoy's 5A growthmedium (Invitrogen)
supplemented with 10% FBS and 2% penicillin–streptomycin at 37 °Cand 5% CO2. Cell cultures were treated for 2 h, unless otherwise noted,
with insulin (4 μg/ml), IGF1 (50 nM), IGF2 (50 nM), EGF (4 μg/ml),
and FGF (0.4 μg/ml) human recombinant proteins, all purchased from
Life Technologies. Wortmannin (Sigma-Aldrich), MK-2206 (Selleck
Chemicals), rapamycin (Selleck Chemicals), PD184352 (Sigma-Aldrich)
were reconstituted in DMSO and incubated with cell cultures at 1 μM
ﬁnal concentration for 4 h. For all above treatments, cells were incubat-
edwithout FBS for 24 h prior to treatment, and reagentswere incubated
with the cells in serum-free conditions. Actinomycin D (Life Technolo-
gies) was resuspended in DMSO and incubated with cell cultures for
4 h at 10 μg/ml ﬁnal concentration.
2.2. RNA extraction, reverse transcription, and qPCR
Adherent cells were harvested in Trizol Reagent (Life Technologies)
following the standard protocol. 1 μg of RNA was used for reverse tran-
scription using the QuantiTect Reverse Transcription Kit (Qiagen) ac-
cording to manufacturer's instructions. Reverse transcription products
were diluted 1:20 in nuclease-free water and 2.6 μl used directly for
qPCR in 10 μl reactions. qPCR reactions were prepared with 1.2 μM
total primers (forward plus reverse primers) and 1X GoTaq® Hot Start
Colorless Master Mix (Promega) supplemented with SYBR® Green I
Nucleic Acid Gel Stain (Roche) at a 1:120,000 dilution. Reactions were
carried out using the LightCycler 480 (Roche) with an initial 2 m dena-
turation step at 95 °C and 40 cycles of a 15 s denaturation step at 95 °C
followed by a 60 s hybridization step at 60 °C, ending with melt curve
analysis. Expression was calculated as 2−ddCt values, normalizing to
β2 microglobulin (β2M) and β-actin genes. The primers (Integrated
DNA Technologies) used for qPCR are detailed in Table S1.
2.3. siRNA knockdown
siRNA oligonucleotides were from Applied Biosystems with the
Silencer® Select custom modiﬁcation to enhance target speciﬁcity and
recommended for non-coding RNA targets. Oligonucleotides were de-
signed from the ~350 base pair highly conserved gVC-In4 region within
the CRNDE locus target sequence, using the Whitehead Institute's
design site (http://sirna.wi.mit.edu/home.php). Three oligonucleotides
(gVC#1, gVC#2, gVC#3)were selected based on greatest target speciﬁc-
ity according to WU-BLAST. siRNA sequences are listed in Table S1.
Stocks were reconstituted in nuclease-free water to give a 50 μM con-
centration and diluted to a 10 nM ﬁnal concentration for all transfec-
tions. siRNAs were transiently transfected into cells either individually
or as a pool. HCT116 or HT29 cells were plated the day before in
antibiotic-free McCoys 5A medium and grown to 60% conﬂuency prior
to commencing transfection. siRNAs were incubated with the lipid-
based DharmaFECT 1 Transfection Reagent (1:200 ﬁnal dilution;
Thermoscientiﬁc) for 20 m. We ﬁnd that transfection efﬁciency for
CRNDE intronic/nuclear transcripts is highly dependent on the concen-
tration of transfection reagent used. The best knockdown was achieved
with a 1:250 ﬁnal dilution of DharmaFECT 1. Complexes were added
to adherent cells using normal culture medium supplemented with
10% FBS but lacking antibiotics for 48 h (except where indicated). For
all experiments, control siRNA oligonucleotide transfections were per-
formed using the same concentrations as the gVC-In4 oligonucleotides:
Silencer®Select Negative Control No. 1 andNo. 2 siRNAs, as the negative
control, and Silencer® Select GAPDH Positive Control siRNA, as the
positive control.
2.4. Exon array hybridization
A novel exon Glue Grant human transcriptome array (“GG-H” array)
[19] was obtained on pre-release from Affymetrix for transcriptomic
analyses. This arraywas chosen because of its greater depth of coverage
at the exon/intron and splice junction level andmore inclusive coverage
of non-coding RNAs. siRNA transfection and insulin treatment, in
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array analysis. High quality RNA (300 ng) from HCT116 siRNA knock-
down cells and HCT116 and LS174T insulin-treated cells, was
subjected to microarray analysis using a slightly revised protocol
from Xu et al. (2011) [19]. Poly A controls were added to each sample
using the Affymetrix GeneChip Poly-A RNA Control Kit. First and sec-
ond strand cDNA was generated using the Ambion WT Expression Kit
(Ambion) with the revisions speciﬁed by [19] for the second cycle.
We used the USB PrepEase DNA cleanup kit for the second cycle
cDNA. The puriﬁed cDNA (20 μg) was split into triplicate reactions
and fragmented with AP Endonuclease (APE1, New England Biolabs)
and uracil DNA glycosylase (New England Biolabs), followed by label-
ing of fragments with deoxynucleotidyl transferase (rTdT) and the
biotin-conjugated nucleotide analogue (DLR-1a) from Affymetrix
GeneChip WT Terminal Labeling Kit (Affymetrix). The triplicate reac-
tions were concentrated into one sample in YM-3 Microcon columns
(Sigma Aldrich). Hybridization mixes were prepared with fragmented,
labeled cDNA plus Control Oligo B2 (Affymetrix), 1X Eukaryotic hybrid-
ization controls (Affymetrix), 2X Hybridization mix (Affymetrix), and
DMSO in 220 μl volumes. The hybridization samples were heated to
99 °C for 5 m then 45 °C for 5 m, and 200 μl of each sample was load-
ed to the GG-H arrays ensuring exclusion of air bubbles. Arrays were
hybridized in the Gene Chip Hybridization Oven 640 (Affymetrix)
for 16 h at 45 °C rotating at 60 rpm. Washing, staining, and scanning
of the arrays were done with the GeneChip Expression Wash, Stain,
and Scan Kit (Affymetrix) and the Gene Chip Fluidics Station 450
(Affymetrix).
2.5. Analysis of expression array data
The original CEL ﬁles generated from the scans were uploaded
into Partek Genomics Suite Software. The signiﬁcantly differentially
expressed exons (p b 0.005, 2-fold cutoff) between arrays/treatments
were determined using 2-way ANOVA, factoring in both treatment
and duplicate experiments. The following comparisons were made (1)
HCT116 negative control siRNAs vs. gVC pool siRNAs (2) HCT116 nega-
tive control siRNAs vs. gVC#3 siRNAs (3) HCT116 no treatment vs. 2 h
insulin treatment (4) LS174T no treatment vs. 2 h insulin treatment.
Using Ingenuity Pathway Analysis (IPA; Ingenuity Systems, www.ipa.
com), exon lists for each comparison were reduced to the gene level
to generate lists comprising only the annotated, non-redundant, differ-
entially expressed genes. The resulting fold changes and p-values listed
for each gene represent the median probe set value if multiple probes
were identiﬁed by Partek. Biological interpretation and gene enrich-
ment were done with both IPA's Core Analysis function (using the de-
fault settings) and with the NIH Database for Annotation, Visualization
and Integrated Discovery (DAVID, http://david.abcc.ncifcrf.gov/) func-
tional annotation tool. In IPA, molecular interaction networks for a
gene list are generated and ranked based on score, which is the negative
exponent of the respective p-value: the likelihood the genes are found
within this network by random chance. For DAVID, genes were clus-
tered according to the gene ontology biological process annotations
(“GOTERM_BP_FAT”).
2.6. Secreted lactate measurements
HT29 cells were transiently transfected with the same gVC siRNAs
used for expression array experiments (gVC pool and gVC#3). After a
24 h transfection period, siRNA complexes were removed and the
cells replenished with fresh media for another 24 h. The culture media
were collected, pre-cleared of cells, and deproteinized using 10 kDa
molecular-weight cutoff spin columns. Media samples were diluted
1:200 and L(+)-lactate concentrationsweremeasuredwith the Lactate
Assay Kit (BioVision) according to themanufacturer's instructions. Cells
from each well were collected and counted (Z2 Coulter Counter,Beckman Coulter) so that the lactate concentrations for a speciﬁc sam-
ple could be normalized to cell number.
3. Results
3.1. CRNDE nuclear transcripts are speciﬁcally downregulated by insulin,
IGF1, and IGF2
According to our analysis of published microarray data from a
human ﬁbroblast cell line [4], siRNA-mediated knockdown of
CRNDE affected expression of a large suite of genes involved in a
number of cellular processes, a subset of which included insulin sig-
naling and related pathways (see Supplementary Text for details and
Tables S2, S3, S4). Because of this evidence and the link between CRC
and insulin-related disorders (e.g. type 2 diabetes and obesity)
[20–23], we were interested to test the effects of insulin/IGF on
CRNDE in colorectal cancer cell lines. Such cells possess mutations
in PI3K and MAPK pathway genes that constitutively activate these
pathways, whichmay result in deregulated insulin signaling and glu-
cose metabolism.
CRC cell lineswere treatedwith insulin and IGFs, and CRNDE expres-
sionwasmeasured by qPCR using transcript-speciﬁc primers (Fig. 1). In
Fig. 1, we show the two categories of CRNDE transcripts: cytoplasmic
versus nuclear. The cytoplasmic transcripts are fully spliced and free
of intronic sequence; conversely, all nuclear-localized transcripts retain
some intronic sequence.We treatedHCT116 andHT29 colorectal cancer
cell lines with either insulin (4 μg/ml, i.e. 690 nM) or one of the two
growth hormones comprising the IGF axis: IGF1 (50 nM) and IGF2
(50 nM). The concentrations selected for the ligands tested are compa-
rable to those used in other studies and they fall within the range rec-
ommended for optimal cell culture growth. It is important to note that
this dosage of insulin is supraphysiological and capable of activating
the IGF1R in addition to the INSR [24]. Because of this we assume that
the observed downstream effects may result from activation of either
or both receptors.
We found that insulin, IGF1, and IGF2 each exerted approximately
55–80% downregulation on nuclear CRNDE transcripts relative to the
untreated control cells (Fig. 2A). These transcripts are represented by
d, f, gVC-In4, In4, and In5 in Fig. 2A. This downregulation of the nuclear
transcripts was in contrast to the effects on the cytoplasmic, fully-
spliced transcripts (represented by transcript h in Fig. 2A and transcripts
b, g, and h in Fig. S1), which were unaffected by insulin and IGFs. The
genes for insulin-like growth factor-binding protein 5 (IGFBP5) and py-
ruvate dehydrogenase kinase 4 (PDK4) are both known to be negatively
regulated by insulin [25,26]. As expected, IGFBP5 and PDK4 expression
showed marked downregulation with all three ligands in HCT116 and
HT29 cells, respectively. Maximal repression of CRNDE transcripts was
observed 2 h post treatment, but this effect is transient as downregula-
tion was not sustained with prolonged treatment (Fig. S1). Longer
insulin incubations resulted in gradual normalization of CRNDE levels,
despite continued replenishment of ligand, with a return to no-
treatment levels by 30 h. PDK4 also demonstrated a similar but slightly
slower rebound response to insulin, suggesting this is not an unusual
pattern for insulin-responsive genes.
The effects of insulin and IGFs do not appear to be shared by other
growth factors, since treatmentwith EGF and FGF for the same time pe-
riod (2 h) had no effect on CRNDE levels in the CRC cell lines used
(Fig. 2B). In these cases, CRNDE nuclear transcript levels did not differ
signiﬁcantly from controls, whereas EGF treatment did increase Sox2
gene expression and FGF that of c-myc (as expected). Because the ef-
fects exerted on CRNDE expression by insulin, IGF1, and IGF2 were
comparable, we assume that all three act through similar mechanisms
to repress nuclear transcripts of this lncRNA. Each ligand treatment
also caused a comparable downregulation of PDK4 and IGFBP5. For
subsequent experiments, insulin was selected to represent the effects
of all three ligands.
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Fig. 1. Alternatively-spliced transcripts derived from the CRNDE locus. The CRNDE locus (on minus strand) and its two classes of transcripts are pictured: (1) the fully-spliced and
cytoplasmic transcripts, represented by Aceview transcripts “b”, “g”, “h”, and (2) the intronic, nuclear-localized transcripts, represented by Aceview transcripts “d” and “f” and by other
transcripts derived from introns 4 (“In4” and “gVC-In4”) and 5 (“In5”), whose exact composition andboundaries remain to bedeﬁned. Red arrows represent the transcript-speciﬁc primers
used for qPCR ampliﬁcation of each amplicon, with dotted arrows indicating that the primer spans an exon-exon junction. In theory, the primer pairs designed should amplify one unique
transcript; however, it is possible the primer pairs amplify qPCR amplicons from additional unknown transcripts.
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mTOR and Raf/MAPK pathways
Insulin and IGFs act primarily through two signaling arms, the PI3K/
Akt/mTOR and Raf/MAPK pathways. To determine whether these path-
ways mediate insulin/IGF's downregulation of CRNDE, cells were treat-
ed with inhibitors of both signaling arms in the presence or absence of
insulin. It is important to note that the HCT116 and HT29 colorectal
cancer cell lines possess gain-of-function mutations in PIK3CA and
KRAS/ BRAF genes, rendering the proteins constitutively activated (see
Fig. 3A) [27]. We used inhibitors of three different components of the
PI3K pathway: Wortmannin (PI3Ki), MK2206 (AKTi) and rapamycin
(mTORi), and one against MEK1/2 of the MAPK pathway: PD184352
(MEKi) (details in Fig. 3A). Cells were serum-starved for 24 h prior to
treatment to prevent any ligand-induced activation of these pathways,
allowing only the constitutive signaling caused by the activating muta-
tions. Cells were pretreated for 2 h with each inhibitor followed by ad-
dition of insulin for another 2 h, and expression of CRNDE's nuclear
transcripts was measured.
Depending onwhich pathway exercises control over CRNDE expres-
sion, we expected to see an inhibition of insulin's effects on CRNDE
when either the PI3K or MAPK pathway was blocked. In HCT116 cells,
we inhibited the PI3K pathway using either PI3Ki, AKTi, or mTORi.
In all three cases, the downregulation of CRNDE's nuclear transcripts
exerted by insulin treatment alone was prevented when each inhibitor
was added prior to insulin (left panel, Fig. 3B). Furthermore, inhibitor
treatments alone (“-Ins”) increased CRNDE nuclear transcript levels
above those of the untreated control cells (red line, Fig 3B), which im-
plies that blockade of the constitutive signaling activation in this path-
way relieves its repression of CRNDE. We conclude from this that
CRNDE nuclear transcripts are negatively regulated by the PI3K path-
way. We next attempted MAPK inhibition with MEKi treatment and
performed equivalent treatments. Interestingly, we found the same be-
havior: MEKi treatment increased baseline CRNDE and PDK4 levels,when used alone, and negated the decrease in CRNDE/PDK4 achieved
by insulin treatment (middle panel, Fig. 3B). Inhibiting both pathways
simultaneously caused effects similar in magnitude to those seen with
the individual inhibitors (right panel, Fig. 3B). Altogether, insulin's
downregulation of CRNDE's nuclear transcripts was prevented – at
least partially – by inhibition of either signaling arm with any of the
four inhibitors tested. PDK4 expression is reported to be inhibited by
both the PI3K andMAPK pathways [25,28,29], and it showed responses
similar to CRNDE nuclear transcripts in all cases. Treatment with actino-
mycin D, an inhibitor of transcription, alongside the signaling inhibitors
prevented the increase in CRNDE transcripts normally achieved with
the latter, indicating that the insulin pathway inhibitors act on CRNDE
at the level of transcript production andnot through transcript stabiliza-
tion (Fig. S2).
HT29 cells showed a nearly identical pattern with these treatments
to the HCT116 cells (Fig. S3). The primary differencewas the synergistic
effect observed herewhen both pathwayswere simultaneously blocked
(PI3Ki + MEKi), supporting the notion that both pathways regulate
CRNDE. Any discrepancies in results from the two cell lines might be at-
tributed to differences in their mutation status for PI3K/MAPK path-
ways: HCT116 is mutated in PI3K and KRAS, and HT29 is mutated in
PI3K and BRAF [30–32] (see Fig. 3A). Since KRAS activates both the
MAPK and PI3K pathways, it might be assumed that constitutive activa-
tion of the PI3K/Akt/mTOR pathway is greater in HCT116 than in HT29,
the latter relying on PI3K mutation alone to activate this pathway. This
was supported by the greater upregulation of CRNDE transcripts with
the PI3K pathway inhibitor treatments alone (i.e. in the absence of insu-
lin, “-Ins”) in HCT116, suggesting greater inhibitory pressure is being
exerted on CRNDE in these cells compared to HT29 cells. It might also
explain the synergism witnessed with dual pathway inhibition in
HT29 but not in HCT116.
To further address the importance of PI3K andMAPKpathwaymuta-
tion status in insulin's repression of CRNDE expression, other cell lines
with alternate PI3K/MAPK mutation proﬁles were tested in a similar
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with a mutation in KRAS but not PIK3CA [27]. Interestingly, the expres-
sion of CRNDE nuclear transcripts hardly responded to insulin and IGFs
in the SW480 cells. Important to note, however, is that their levels were
increased by all pathway inhibitors in a similar fashion to HCT116 and
HT29 cells (Fig. S4, top graph). Combined PI3K andMEK inhibitor treat-
ment synergized to give the greatest increase in expression, an effect
also observed in HT29 cells. The data indicate that in SW480 cells acti-
vated PI3K and MAPK pathways already repress CRNDE nuclear tran-
scripts to basal levels.
Because mutual activation of both PI3K and MAPK pathways nearly
always exists in CRC cell lines [33–36], we also tested the MCF7 breast
cancer cell line. These cells have activating mutations in PIK3CA but
not in MAPK pathway genes [27]. This allowed an examination of
insulin's effects on CRNDE in a non-CRC cell line and a PI3K-onlymutant
context. InMCF7 cells, insulin and IGFs exerted a repressive effect on the
same nuclear CRNDE transcripts with a similar magnitude to that seen
in HCT116, and all inhibitors compromised if not fully abrogated the ef-
fects of insulin (Fig. S4, bottom graph). In contrast to CRC cells, however,the inhibitors hadminimal effect on CRNDEwhenused in the absence of
insulin.
Altogether, we see from the use of multiple cell lines that CRNDE
responds differently to insulin/IGFs and PI3K/MAPK pathway inhibitors
in various cellular contexts, likely due to variances in the mutation
status and/or overall activity levels of insulin/IGF signaling pathway
components. Yet, regardless of mutation status, inhibition of either
pathway is capable of preventing insulin's repression of CRNDE nuclear
transcript expression, demonstrating that CRNDE is a downstream
target of both PI3K/Akt/mTOR and MEK signaling.
3.3. RNAi of CRNDE gVC-In4-containing transcripts in CRC cells affects insulin
signaling responses
Because the repressive effects of insulin and IGF treatment were
restricted to nuclear-localized CRNDE transcripts, these were the focus
of our functional studies, particularly the highly-conserved gVC-In4
region. This region of the CRNDE genomic sequence exhibits high se-
quence conservation across vertebrate species and is included in many
AB
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377B.C. Ellis et al. / Biochimica et Biophysica Acta 1843 (2014) 372–386transcripts [1,3]. The other insulin/IGF-affected transcripts (e.g. d, f, In4-
and In5-containing transcripts) potentially contain gVC-In4 also, as the
PCR primers used to detect them do not preclude its inclusion (see
Fig. 1).
3.3.1. A large suite of genes is affected by knockdown of gVC-In4 transcripts
We performed RNAi to determine genes whose expression was
affected by gVC-In4 transcripts, using HCT116 cells because of their rel-
atively high transfection efﬁciency. siRNAswere designed to speciﬁcally
target the 300-nucleotide gVC-In4 sequence. Three different siRNA oli-
gonucleotides targeting gVC-In4 were transiently transfected into cells
as a pool (“gVC pool”) (Fig. 4A). Transfection with the oligonucleotide
#3 (“gVC#3”) individually showed the most comparable knockdown
of gVC-In4 transcripts to the gVC pool, and thus, knockdown withgVC#3 alonewas also used to conﬁrm results. In general, we ﬁnd nucle-
ar CRNDE transcripts to be partially resistant to siRNA-mediated knock-
down. With optimization of the transfection protocols, we achieved
knockdown of gVC-In4 transcripts to 37% and 52% of control levels
with gVC pool and gVC#3, respectively (Fig. 4B). We saw comparable
knockdown effects on other CRNDE nuclear transcripts (d, f, and In4-
containing transcripts) but minimal effects on cytoplasmic transcript,
h, and transcripts from CRNDE's nearest gene neighbors, IRX5 and IRX3
(only shown for gVC pool-transfected cells).
Transcriptomic changes were evaluated in the knockdown cells
using the new GG-H expression microarray, which permitted more
thorough evaluation at the exon level of both coding and non-coding
transcripts than predecessor arrays. Differentially-expressed exons
(≥2-fold change, p b 0.005) were identiﬁed in both the gVC pool- and
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each list of affected exons to 553 and 738 unique annotated genes, re-
spectively (Fig. 5A). At the cutoffs we selected, 316 of these genes
were common between both lists (Fig. 5A and Table S5) of which 138
were upregulated and 178 downregulated. A large number of the 316
genes encode enzymes (106 of 316 genes), including 37 kinases/
phosphatases. The top ten most up and downregulated genes for each
knockdown event are shown in Table 1, and the expression patterns be-
tween the gVC pool and gVC#3 knockdowns correlated well.
As an independent analysis, we also examined the effect of CRNDE
knockdown on alternative splicing. The GG-H exon array possesses
probesmapping against not only gene exons/introns but also splice junc-
tions,whichpermits in-depth evaluation of alternative splicing using the
Junction and Exon Toolkits for Transcriptome Analysis (JETTA) software
tool [37]. With JETTA we identiﬁed 130 differentially expressed exons
(including multiple exons from the same genes) within genes whose
overall expression was largely unaltered (i.e., exhibited less than a 2-
fold change) following gVC-In4 knockdown (Supplementary Text and
Table S6). Therefore, CRNDE appears to regulate genes at both tran-
scriptional and post-transcriptional levels.
3.3.2. Genes affected by gVC-In4 knockdown overlapwith insulin/IGF-related
gene pathways and networks
The 316 differentially expressed genes common to both knockdown
experiments were subjected to IPA Core Analyses to determine the asso-
ciated gene networks, pathways, and cellular functions. The affected
genes most strongly correlated with canonical pathways that directly orFig. 5. Transcriptomic analysis of siRNA-mediated gVC-In4 knockdown in HCT116 cells. (A) RN
were hybridized to the human oligonucleotide GG-H array. Partek and IPA were used to genera
between gVC-In4 knockdown cells and negative control siRNA knockdown cells. The overlap
pathways affected by CRNDE knockdown are demonstrated. The genes are classiﬁed by gene
downregulation in gVC-In4 knockdown cells relative to controls. * indicates validation of the in
acid, IP3: inositol trisphosphate, CDP-DAG: cytidine diphosphate-diacylglycerol, glucose-6-P
phatidylinositol 4,5-bisphosphate, PIP3: phosphatidylinositol 3,4,5-bisphosphate, G-3-P: glyce
DAG: diacylglycerol, PA: phosphatidic acid; PEP: phosphoenolpyruvic acid.indirectly relate to downstream insulin/IGF signaling, particularly those
mediated by phosphoinositides (e.g. PI3K pathway; Table 2). The 316
genes are well represented in the high-scoring IPA molecular interaction
networks of “developmental disorder, hereditary disorder, andmetabolic
disease” (network 1, score = 41) and “cell morphology, embryonic de-
velopment, and lipid metabolism” (network 2, score = 36) (Table S7).
A DAVID analysis (http://david.abcc.ncifcrf.gov) was also performed
on these 316 genes using the functional annotation tool. The genes
clustered best in the top-scoring biological process gene ontology
(GO) term of “response to oxidative stress” (enrichment score: 4.22,
p = 1.4e-06). CRNDE's inﬂuence on genes that respond to oxidative
stress supports the identiﬁcation by IPA of hypoxia-inducible factors
(HIFs) as upstream regulators of CRNDE-controlled genes in ﬁbroblasts
(see Supplementary Text and Table S4).
According to the DAVID analyses, many of the genes whose expres-
sion was affected by CRNDE knockdown are classiﬁed by gene ontol-
ogies of glucose metabolism and lipid/phospholipid metabolism. This
was also true for the genes detected as alternatively spliced by JETTA
(see Supplementary Text and Table S6). Several of these genes, and
the direction of their change in expression upon gVC-In4 knockdown,
are depicted in a diagram that relates the associated pathways and reac-
tions (Fig. 5B). The genes are responsible for glucose-6-phosphate me-
tabolism, fatty acid/lipid synthesis and breakdown, and phospholipid
second messenger signaling. Differential expression of several genes
was validated with qPCR in HT29 cells that had been transfected with
gVC pool and gVC#3 siRNAs in the same manner as the HCT116 cells
(Fig. S5a). Even though the knockdown of gVC-In4 transcripts (50–A samples from the HCT116 knockdown cells described in Fig. 4B (duplicate experiments)
te lists of differentially expressed exons and non-redundant annotated genes, respectively,
of these two sets of genes is shown in the Venn diagram. (B) Metabolic processes and
ontologies of glucose, lipid, or phospholipid metabolism/signaling. Arrows indicate up or
dicated gene's differential expression by qPCR in HT29. Abbreviations: TCA: tricarboxylic
: glucose-6-phosphate, GLUT: glucose transporter, PI: phosphatidylinositol, PIP2: phos-
raldehyde 3-phosphate, GPC: Glycerol phosphorylcholine, PtdCho: phosphatidylcholine,
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ﬁcient enough to induce expression changes in target genes comparable
to those in HCT116 knockdown cells. Genes validated by qPCR are
marked in Fig. 5B with an asterisk (*). gVC-In4 knockdown also affected
the expression of genes (FLOT1, TRIP10/CIP4/2, CBL) involved in the lipid
raft-localized Cbl/CAP/TC10 pathway, which is stimulated directly by
insulin/INSR to regulate cellular glucose uptake, independently of
PI3K/Akt-mediated glucose uptake [38–40].
Due to the potential for off-target/nonspeciﬁc effects by the gVC#3
siRNA, we also tested the effects of the other two siRNAs within the
gVCpool, gVC#1 andgVC#2,which target independent, non-overlapping
regions of the gVC-In4 region from gVC#3 (refer to Fig. 4A). These
oligonucleotides were transfected into HCT116 cells, but because
gVC#1 and gVC#2 had less potent knockdown efﬁciency than gVC#3,
different conditions were tested. At 96 h transfection time periods,
we achieved a similar gVC-In4 knockdown to the gVC#3 siRNA with
gVC#1 and a high-dose combination of gVC#1 + #2 (1.5-fold concen-
trations of each siRNA and the transfection agent) (Fig. S5b). Under
these conditions, knockdown with the alternate gVC siRNAs induced
comparable changes to gVC#3 siRNA in the expression of keymetabolic
genes, for which qPCR data are shown in Fig. S5a. This conﬁrmed a
similar effect on metabolism-related genes when independent regions
of gVC-In4 were targeted in our knockdown experiments.
Altogether, we see that gVC-In4 knockdown affected the expression
of a subset of genes (with key representatives conﬁrmed by qPCR) that
are associated with glucose/lipid metabolism. The decrease in the ex-
pression of genes responsible for glucose-6-phosphate anabolic reac-
tions (GYS1, G6PC3, ISYNA1, G6PD), the decrease in FASN expression,
and the increase in ACADVL and ACOT9 expression all suggest that gVC-
In4 overexpression might push the cell towards anabolic metabolism.
3.3.3. Knockdown of gVC-In4 decreases lactate secretion and expression of
GLUT4 and MLXIPL in CRC cells
As shown above, we observed a subset of knockdown-affected genes
associated with anabolic metabolism of glucose and lipids (see Fig. 5B).
We therefore assessed a role for CRNDE nuclear transcripts in the shift
to aerobic glycolysis (as seen in tumorigenesis) bymeasuring lactate se-
cretion, a prominent metabolic change associated with theWarburg ef-
fect. We tested the effect of gVC-In4 transcript knockdown on secreted
lactate levels relative to transfection with negative control siRNAs. The
HT29 cell line was selected for these experiments because of its report-
edly high levels of aerobic glycolysis, which cause 85% of input glucose
to be converted to lactate [41,42]. It was also the cell line in which we
detected the greatest repressive effect on CRNDE expression by insu-
lin/IGF. The lactate concentration was measured in the knockdown
cells' culture medium using a metabolic assay (Fig. 6A). The secreted
lactate concentration (normalized for cell number within each sample)
was signiﬁcantly lower in the gVC knockdowns than in the controls
(1.9- and 2.3-fold with gVC pool and gVC#3, respectively; p b 0.05).
Thus, knocking down gVC-In4 transcript levels appears to decrease
the amount of lactate produced by cancer cells.
The decrease in lactate secretion could result from lower rates of gly-
colysis or from increased conversion of pyruvate to acetyl CoA rather
than to lactate. To examine factors that affect glucose uptake into the
cell, we measured expression of GLUT4, the insulin-regulated glucose
transporter. Insulin stimulates the translocation of GLUT4 to the plasma
membrane and GLUT4 allows facilitated transport of glucose into the
cell [38]. GLUT4 expression has been linked directly with carbohydrate
metabolism [43,44]. In HT29 knockdown cells, we used qPCR to show
decreased GLUT4 expression (62% and 49% reduction for gVC pool and
gVC#3, respectively) (Fig. 6B), suggesting that CRNDE positively regu-
lates GLUT4 transcript levels and perhaps glucose intake. Decreased glu-
coseﬂux could contribute to the decreased lactate secretion observed in
CRNDE knockdown cells. We also found that MLXIPL (also known as
CHREBP) expression, which is regulated by GLUT4 [45], was decreased
to similar levels as GLUT4 in the knockdown cells. The MLXIPLtranscription factor is known to control genes involved in glycolysis
and lipogenesis [46–49], andMLXIPLwas the secondmost downregulat-
ed gene of the 316 identiﬁed by microarray (Table S5). GLUT4 and
MLXIPL expressionwere also decreased in HCT116 after a 48 h transfec-
tion period, though not quite to the samemagnitude as inHT29 (Fig. 6B)
despite comparable decreases in gVC-In4 transcripts.Wedid see a time-
dependent effect on GLUT4 and MLXIPL, as shown in HCT116; both
transcripts decreased even further after a 96 h transfection period
(62% and 86% reduction, respectively), and this coincidedwith a greater
decrease in gVC-In4 at this time (77% reduction). This suggests that
CRNDE's effects on metabolic gene expression are sustained/intensiﬁed
over longer time periods.
3.3.4. A subset of insulin-regulated genes is also affected by gVC-In4
knockdown in HCT116
In order to determine whether CRNDE mediates a portion of insulin
responses, we examined the genes affected by both gVC-In4 transcript
knockdown and insulin treatment in CRC cells. HCT116 cells were treat-
ed with insulin for 2 h (the time required for maximal CRNDE repres-
sion), and subjected to microarray analysis under identical conditions
to the knockdown cells (see Fig. 5A). There were 930 annotated
genes, identiﬁed by IPA, that were affected by insulin in HCT116 cells
(Table S8), suggesting that (despite the activating mutations in its sig-
naling pathways) this cell line is quite responsive to insulin. We found
62 and 75 genes common to both insulin treatment and the gVC pool
and gVC#3 knockdowns, respectively (Fig. 7A; Tables S9 and S10);
thus, a total of 97 genes were affected by both insulin treatment and
gVC-In4 knockdown. According to IPA, these 97 genes are linked pri-
marily with cancer-associated cell functions, particularly invasion, pro-
liferation, and migration processes (Table S11). It is worth noting that
gVC-In4 knockdown changed the expression of several genes involved
in PI3K/AKT signaling (e.g. SHC1, RELA, IKBKG, ILK, PPP2R1B) and insulin
receptor signaling (e.g.GYS1, AKT2, CBL, TRIP10, ASIC1) (see Table 2) that
were not affected by insulin treatment. One possibility is that suchmol-
ecules may be controlled by insulin exclusively at the post-translational
level (e.g. phosphorylation). Another possibility is that because some of
thesemolecules play roles early in the signaling cascade and/or are reg-
ulators of insulin/IGF pathways, CRNDE regulation of their expression
may act as part of a feedback loop to regulate upstream components
of insulin signaling cascades.
Of the 97 genes affected by both insulin treatment and CRNDE
knockdown, 40 are shared between the two gVC-In4 knockdown
events, identifying a subset of high-conﬁdence, shared insulin and
gVC-In4 gene targets (Fig. 7A and Table S12). This overlap between
gene sets is statistically highly signiﬁcant (p = 2.7e-07). As a negative
control, the LS174T cell line (which does not express CRNDE [1]) was
also treated with insulin and evaluated alongside the HCT116 cells.
Of the 40 shared genes in HCT116, none was differentially expressed
with insulin treatment of LS174T.While not conclusive, this observation
is consistent with a dependence of the differential expression of these
genes upon the presence of CRNDE transcripts in the cell (Fig. 7B and
Table S13).
Remarkably, all 40 shared genes within HCT116 clearly divide into
just two high-scoring IPA molecular interaction networks: “cancer,
cellular function and maintenance, molecular transport” (Fig. S6a;
score = 54; 22 genes involved) and “nervous system development
and function, organ morphology, cell-to-cell signaling and interaction”
(Fig. S6b; score = 42; 18 genes involved). There are no shared genes
between the two networks, underscoring the division of these 40
genes into two distinct groups. The 22 genes within the ﬁrst network
are associated with cancer (e.g. head and neck cancer, p = 7.3e-05, 8
genes, and brain cancer, p = 8.8e-04, 5 genes) and organ morphology,
suggestive of an overlap between CRNDE's functions and insulin/IGFs'
mitogenic and/or developmental functions. The second network is clus-
tered around the polyubiquitin enzyme, ubiquitin C (UBC). Central to
both networks are molecules necessary for insulin signaling (e.g.
Table 1
The top ten most up and downregulated genes affected by gVC-In4 knockdown.a
gVC pool gVC#3
Entrez gene name p-Value FCb p-Value FCb
WBP2 WW domain binding protein 2 2.17E-07 20.59 3.12E-07 18.18
KLHDC3 Kelch domain containing 3 2.56E-07 16.93 1.88E-07 18.76
SUMF2 Sulfatase modifying factor 2 4.95E-06 10.61 4.15E-05 6.14
GPX4 Glutathione peroxidase 4 3.71E-07 8.57 3.77E-06 5.12
TRIP10 Thyroid hormone receptor interactor 10 8.18E-05 8.15 4.15E-05 9.88
FAT1 FAT tumor suppressor homolog 1 (Drosophila) 1.63E-03 5.15 4.07E-04 7.15
CLTC Clathrin, heavy chain (Hc) 1.32E-06 5.01 4.05E-05 2.89
PNPO Pyridoxamine 5′-phosphate oxidase 6.50E-05 4.90 2.89E-05 5.83
IMPDH2 IMP (inosine 5′-monophosphate) dehydrogenase 2 8.46E-04 4.53 7.28E-04 4.81
ERGIC3 ERGIC and golgi 3 7.24E-05 4.45 3.20E-04 3.39
KCNIP3 Kv channel interacting protein 3, calsenilin 1.69E-03 −3.23 1.71E-03 −3.25
MICALL1 MICAL-like 1 1.31E-03 −3.23 2.94E-03 −2.81
SLC6A9 Solute carrier family 6 (neurotransmitter transporter, glycine), member 9 8.78E-04 −3.30 2.08E-03 −3.36
EPB41L2 Erythrocyte membrane protein band 4.1-like 2 3.22E-04 −3.31 6.98E-04 −2.92
SCYL1 SCY1-like 1 (S. cerevisiae) 1.90E-04 −3.33 6.80E-05 −3.97
EPS8L2 EPS8-like 2 4.48E-06 −3.48 6.20E-05 −3.85
NOTCH3 Notch 3 1.58E-03 −3.50 1.23E-03 −2.22
GDPD3 Glycerophosphodiester phosphodiesterase domain containing 3 4.36E-03 −3.64 3.96E-03 −4.00
MLXIPL MLX interacting protein-like 5.28E-04 −4.01 2.41E-03 −2.70
GPS2 G protein pathway suppressor 2 1.94E-03 −4.64 1.84E-03 −4.70
a From the list of 316 genes differentially expressed by gVC-In4 knockdown (details in Fig. 5A).
b FC: fold change; positive values indicate upregulated expression and negative values downregulated expression in knockdown cells relative to controls.
381B.C. Ellis et al. / Biochimica et Biophysica Acta 1843 (2014) 372–386insulin, PI3K, Akt, Ras, MAPK, ERK, EIF2B4), again stressing the impor-
tance of these key signaling pathways in gene regulation by CRNDE nu-
clear transcripts.
4. Discussion
4.1. Upstream regulation of CRNDE expression by insulin/IGF signaling
pathways
Many lncRNA genes have now been identiﬁed, but the function and
regulation of these transcripts are still relatively unexplored. CRNDE is
the ﬁrst lncRNA reported to respond to insulin/IGF or to their major
downstream pathways, the PI3K and MAPK signaling cascades. We
ﬁrst noticed an apparent connection between CRNDE knockdown and
insulin/IGF signaling in an analysis of expression microarray data from
human ﬁbroblasts. We therefore questioned whether such a relation-
ship also existed in other contexts, and speciﬁcally in CRC cells. Using in-
sulin treatment and siRNA knockdown of CRNDE in HCT116 and HT29
cells, we showed negative regulation by these pathways of nuclear
CRNDE transcripts and, in turn, regulation by CRNDE of genes involved
in insulin-mediated signaling. Altogether, there is evidence of a role
for these nuclear lncRNA transcripts in controlling insulin/IGF-related
processes in both normal and cancer cells. While we have focused
here on nuclear CRNDE transcripts, it should be noted that expressionTable 2
The top canonical pathways associated with genes affected by gVC-In4 knockdown.
Ingenuity canonical pathways -log(p-value) Ratioa Moleculesb
Gαq signaling 3.01 9/159 RELA,AKT2,IKBKG,PLD2
IL-15 signaling 2.41 5/65 SHC1,STAT6,RELA,AKT2
PTEN signaling 2.36 7/132 SHC1,RELA,AKT2,IKBKG
ILK signaling 2.33 9/189 RELA,AKT2,FLNA,ILK,VI
PI3K/AKT signaling 2.28 7/137 SHC1,RELA,AKT2,IKBKG
Protein kinase A signaling 2.26 14/383 RELA,PTPRD,ADCY3,PTP
Erythropoietin Signaling 2.24 5/74 SHC1,RELA,AKT2,CBL,PR
PI3K signaling in B lymphocytes 2.18 7/133 RELA,AKT2,IKBKG,CBL,I
Phospholipase C signaling 2.18 10/248 HDAC6,SHC1,RELA,PLD
Axonal guidance signaling 2.16 15/461 KLC1,AKT2,PLXNA3,EPH
Insulin receptor signaling 2.11 7/135 SHC1,AKT2,EIF2B4,GYS
a Ratio: number of knockdown-affected genes (out of 316 genes)/number of genes involved
b Molecules: the knockdown-affected genes present in the indicated canonical pathway.of both nuclear and cytoplasmic transcripts is elevated in CRC. Because
of the overlapping sequence content and multiple transcript isoforms,
different approaches will be required to elucidate the function of cyto-
plasmic CRNDE transcripts.
A feature of the transcriptional response to insulin of both CRNDE
nuclear transcripts and PDK4 was an initial repression followed by a
return over 24–48 h to initial levels. Prolonged insulin treatment can
lead to desensitization of insulin-induced signaling, and in cultured
muscle cells this was seen to correlate with reduction in levels of IRS1
and IRS2 proteins [50]. A similar feedback mechanism could explain
the transient nature of insulin repression in CRC cell lines. Mechanisti-
cally, such a loop could involve CRNDE target genes, some of which
are upstream components in insulin signaling. The presence of constitu-
tive activating mutations in the signaling pathways is also expected to
reduce insulin sensitivity and the capacity of the cells to sustain a
prolonged upregulation of these kinases.
Transcriptomic regulation by insulin/IGF in general may depend on
mutation status of the cell. As shown in Figs. 3, S2, and S4, there were
differences in CRNDE and PDK4 expression among CRC cell lines in re-
sponse to treatments with insulin and inhibitors of insulin signaling.
The ability of PI3K/MAPK pathway mutations to interfere with insulin/
IGF-driven transcriptional responses of CRNDE and other genes needs
further investigation. For example, different activating mutations in
PIK3CA and PTEN deletion have recently been shown to associate with,GYS1,ADRBK1,ITPR3,PLCB3,PRKCG
,AXL
,CBL,ILK,CSNK2B
M,ITGB8,PPP2R1B,ACTN1,TESK1
,GYS1,ILK,PPP2R1B
N18,PRKCG,CDC25B,AKAP13,GYS1,PTPRU,FLNA,ITPR3,ADD1,PLCB3,PTPRA
KCG
TPR3,PLCB3,PLEKHA1
2,MPRIP,AHNAK,ITPR3,ADCY3,PLCB3,PRKCG
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in the Ingenuity Pathway Analysis (IPA) canonical pathway.
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Fig. 6. CRNDE knockdown effects on lactate secretion and expression of GLUT4 and MLXIPL in CRC cells. (A) HT29 cells were transfected with the gVC pool, gVC#3, or negative control
siRNAs (veriﬁcation of knockdown of gVC-In4 transcripts shown in panel B, left graph). Cell culture media weremeasured for L(+)-lactate using an enzymatic assay. Columns represent
the lactate concentration (pM) normalized per cell, and bars represent the standard errors for triplicate knockdown experiments. * denotes signiﬁcance (p b 0.05) relative to the negative
controls as determined by ANOVA and Student's t-tests. (B) HT29 (left) and HCT116 (right) were transfectedwith negative control or gVC siRNAs for the indicated times, and the expres-
sion of gVC-In4 transcripts and the glucose metabolism genes, GLUT4 and MLXIPL, was measured by qPCR. Expression for each gene is relative to expression in negative control siRNA-
transfected cells (1.0, red line). Columns represent the average 2−ΔΔCT values and bars represent standard errors from three independent experiments.
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tion status affects insulin/IGF signaling/sensitivity and its impact on
cancer cell growth.
The effect of insulin/IGFs on nuclear but not on cytoplasmic CRNDE
transcripts was intriguing. Studies in Drosophila have demonstrated a
broad impact of insulin on alternative splicing [52]; in mammalian
cells, insulin-regulated alternative splicing has been demonstrated for
a number of speciﬁc genes. For example, both protein kinase CδII and
protein kinase CβII splice variants are regulated by insulin through the
Akt kinase-mediated phosphorylation of splicing factors [53,54]. Since
CRNDE displays complex splicing patterns with multiple transcript
isoforms, insulin may act through such pathways to promotemore efﬁ-
cient splicing, thereby decreasing intronic (and thus nuclear) transcript
expression; however, we did not detect increases in the known spliced
transcripts (e.g. b, g, h), even after 48 h (see Fig. S1). There is also evi-
dence linking the use of alternate transcription start or termination
sites with alternative splicing [55]. It is possible that the two classes of
transcripts are driven by different transcription factors and transcrip-
tion complexes, potentially using different subsets of transcription
start sites and resulting in different splicing patterns.
4.2. Downstream regulation of metabolic genes by CRNDE
Independent of our observations that insulin/IGF and their signaling
pathways regulate CRNDE expression, we showed that knockdown of
nuclear CRNDE transcripts affects the expression of genes involved in
insulin-mediatedprocesses. The speciﬁc genes affected suggest a positive
relationship of gVC-In4 transcript expression with the anabolic utiliza-
tion of glucose-6-phosphate (e.g. inositol synthesis, pentose phosphatepathway, glycogenesis, fatty acid synthesis) and phospholipid hydrolysis.
A role for CRNDE inmediating insulin signaling is supported by the over-
lap that we found between genes affected by gVC-In4 knockdown and
insulin treatment in HCT116 cells (Fig. 7A). However, the knockdown-
affected glucose metabolic genes for the most part were not included
in this overlap group, in contrast to what might have been expected.
Instead, the subset of genes affected by both CRNDE knockdown and
insulin displays cancer-associated functions (Table S11), which could
suggest that insulin plays more of a mitogenic role in HCT116.
The number of gVC-In4 gene targets shared with insulin-regulated
genes that we have reported is likely an underrepresentation, due to
various factors. First, the PI3K/MAPK-activating mutations in HCT116
likely affect the genes regulated by both CRNDE and by insulin in
these cells. Since they may attenuate the cell's response to insulin,
such mutations could minimize gene expression changes. Second, ex-
perimental conditions could have further limited the degree of gene
overlap. For one, the effects of siRNA knockdown and insulin treatment
were measured at different time-points: the former after 48 h and the
latter after only 2 h. Both times correspond to the maximum effect on
CRNDE nuclear transcript expression. Second, insulin treatment neces-
sitates the use of serum-free (0% FBS) conditions due to the presence
of IGF in serum, while siRNA knockdown is compromised signiﬁcantly
in the absence of serum and thus is performed in 10% FBS. The insulin
and siRNA treatments achieved maximum and comparable reduction
of CRNDE levels. Despite the differences in cell context and experi-
mental design, we nevertheless observed an overlap between genes
regulated by insulin and CRNDE. It is therefore likely that CRNDE does
mediate a portion of insulin's actions. On the other hand, it is reasonable
to expect that genuine differences would exist in the transcriptomic
40 nonredundant, annotated genes common between comparisons 1, 2, and 3
276 387215
(2) gVC #3 vs controls
738 total genes
40
22 35
833
(1) gVC pool vs controls
553 total genes
(3) HCT116+insulin vs controls
930 total genes
272
40
875
15
4
0 nonredundant, annotated genes common between comparisons 1, 2, and 3
(2) LS174T+insulin vs
controls
164 total genes
(1) gVC-In4 knockdowns 
vs controls
316 total genes
(3) HCT116+insulin vs controls
930 total genes
145
A
B
Fig. 7. Gene overlap between gVC-In4 knockdown and insulin treatment in HCT116 cells and LS174T cells. (A) Microarray hybridizations and transcriptomic analyses were performed on
RNA samples from HCT116 cells treated with insulin (4 μg/ml, 2 h) in duplicate experiments, using the same methods as described in Fig. 5A. IPA was used to identify the genes shared
between this dataset and the 316 high-conﬁdence genes affected by gVC-In4 knockdown, represented by the Venn diagram. (B) Gene overlapwas alsomeasured between all three groups
assessed in (A) and LS174T cells (which do not express CRNDE) treated with insulin. In this diagram, the 316 high-conﬁdence gVC knockdown genes are represented by a single circle/
group. Transcriptomic analyses for insulin-treated LS174T cells were identical to those described for HCT116 in (A).
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discussed below, CRNDE likely plays additional roles that are unrelated
to insulin signaling.
The evidence that CRNDE transcripts are regulated by both the PI3K
and MAPK signaling pathways, which are implicated in numerous
critical cellular processes, indicates this lncRNA could be involved in a
number of functions. An important observation from the CRNDE knock-
down and insulin treatment transcriptomic data is that many insulin-
dependent processes are likely to be independent of CRNDE, and that
insulin signaling represents only a portion of CRNDE's functions and
modes of regulation. IPA showed the knockdown-affected genes to beinvolved in diverse molecular interaction networks, canonical path-
ways, and biological functions, outside of insulin/IGF-related processes.
Of particular interest is the network centered on UBC that contained 18
of the 40 high-conﬁdence genes regulated by both insulin/IGF and
CRNDE (Fig. S6b); a number of these genes have been implicated in
colorectal and other cancers. Furthermore, IPA predicted numerous
upstream regulators for the affected genes (Tables S4 and S14), the
estrogen receptor being the most signiﬁcant in HCT116. Recently, the
estradiol-activated estrogen receptor was reported to transcriptionally
activate HOTAIR, a well-studied lncRNA with functions in epigenetic
control [56].HOTAIR expression is elevated in both breast and colorectal
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It may be that many lncRNAs, including HOTAIR and CRNDE, are regu-
lated by hormones, growth factors and other bioactive agents. While
we have focused here on selective functions for CRNDE in insulin/IGF
signaling, it is likely that the nuclear transcripts for this lncRNA play a
role in diverse cellular processes, and in turn may be regulated by a
number of ligands and pathways.
4.3. CRNDE as a potential mediator of the Warburg effect
A hallmark of cancer is an alteration in metabolism known as the
Warburg effect, in which highly-proliferating tumor cells switch from
oxidativemetabolism to aerobic glycolysis [16,59]. In aerobic glycolysis,
pyruvate is converted into lactate rather than into acetyl CoA, the latter
ofwhich fuels the tricarboxylic acid (TCA) cycle in oxidativemetabolism
[15]. An abundance of nutrients in the tumor environment along with
elevated glycolytic rates provide the tumor cells with sufﬁcient energy,
simultaneously allowing cells to redirect the carbon backbones generat-
ed from glycolysis into anabolic processes. The anabolic products pro-
vide the biomass needed for cell division, thus giving the tumor cell a
selective growth advantage [60,61]. Normal colon cells are unique in
that they utilize butyrate rather than glucose as their primary energy
source [62,63]; it is the beta-oxidation of butyrate (rather than glucose
catabolism) that yields acetyl CoA to fuel the TCA cycle. However, colon
cancer cells make the switch from a butyrate- to glucose-utilizing
metabolism, which is thought to be a consequence of the Warburg
effect [64–67]. As a result, many genes deregulated in CRC are ex-
pected to be associatedwith glucosemetabolism. Accordingly, muta-
tions arise in CRC within insulin/IGF's canonical signaling pathwaysTRANSCRIPTOMIC
G6P metabolism (+)
Fatty acid synthesis (+)
Lipid catabolism (-)
Phospholipid signaling
P
Insulin
PI3K
mTOR
Akt/PKB
CRNDE n
Anabolic me
No CRNDE expression
Butyrate-utilization
COLON
Carcinogenesis
Glucose-
Fig. 8.Model for CRNDE's role in insulin signaling and metabolism. Insulin/IGFs repress CRNDE
elevated levels of CRNDE nuclear transcripts in CRC cells increase glucose metabolism, lacta
insulin/IGF signaling pathways, but the extent to which these pathways can be attenuated lik
in black represent what was experimentally observed in this study, while text/arrows in blue
correlation with CRNDE expression, respectively.(PI3K andMAPK) which potentiate theWarburg effect by facilitating
glucose uptake [66]. CRNDE's effects on central/energy metabolism
genes (discussed below) and its elevated expression in CRC suggest
that it may be intimately involved in the altered glucose metabolism
characteristic of neoplastic colon cells.
In support of a role for CRNDE in the Warburg effect, gVC-In4 tran-
script knockdown affected the expression of genes responsible for
the metabolism of glucose 6-phosphate and lipids/phospholipids.
These transcriptional responses were accompanied by a phenotype of
decreased lactate secretion, and thus reﬂect a decrease in aerobic glycol-
ysis (Warburg effect) occurring in response to CRNDE knock-down
(Fig. 6A). The decreased lactate secretion observed with CRNDE knock-
down could be a consequence of decreased glycolytic rates or a prefer-
ence for pyruvate conversion into acetyl CoA rather than into lactate,
or both. Supporting the former option, we detected a decrease in
GLUT4 and MLXIPL expression (Fig. 6B), which suggests a decrease in
glucose uptake in the knockdown cells. Supporting the latter option,
we found that PDK4 expression was decreased (Fig. S5) by CRNDE
knockdown, a change that encourages the oxidative metabolism of
glucose by enhancing the conversion of pyruvate into acetyl CoA. Con-
versely, high CRNDE expression (as found in CRC)may promote glucose
uptake and its subsequent catabolism into lactate rather than into pyru-
vate, thus contributing to the Warburg effect.
4.4. A model for CRNDE nuclear transcripts in CRC and insulin signaling
More information is needed to understand how the mechanisms
behind CRNDE's upegulation in cancer and its repression by insulin/
IGF are related. CRNDE is a complex gene with many transcripts, whosePHENOTYPIC
Lactate secretion (+)
(+)
P
IGF
INSR/IGFR
Ras GTP
Raf
MEK
ERK
uclear transcripts
Epigenetic mechanisms?
2h
tabolism/ Warburg effect
utilization
Feedback mechanisms
PI3K/MAPK 
mutations
No PI3K/MAPK 
mutations
intronic transcripts via the two signaling pathways, PI3K/AKT/mTOR and Raf/MAPK. The
te secretion and lipid synthesis. CRNDE nuclear transcripts also feedback on upstream
ely depends on whether constitutively activating mutations are present. Text and arrows
are speculation. (+) and (−) indicate an experimentally-observed positive or negative
385B.C. Ellis et al. / Biochimica et Biophysica Acta 1843 (2014) 372–386effects may differ with transcript composition (e.g., differences in exon
content and retained intronic regions), the nature of the cell (non-cancer
or cancer), and themutation status of major signaling pathways. The up-
regulation of CRNDE in CRC and its downregulation by insulin/IGF is
seemingly paradoxical but may relate to different requirements for
metabolic processes and cell division — elevated CRNDE expression
may be required for promoting anabolic pathways in the context of mi-
togenic activation by insulin/IGF.
Whilemany questions remain, we propose amodel for CRNDE's role
in insulin/IGF signaling and metabolic functions in CRC cells based on
our current knowledge (Fig. 8). It is well known that carcinogenesis in
the colon causes the cells to change to a glucose-utilizing metabolism
and aerobic glycolysis (Warburg effect). We suggest that the upregula-
tion of CRNDE in CRC is central to this metabolic shift, which is support-
ed by the transcriptomic changes and effect on lactate secretion seen in
CRNDE knockdown cells. From the speciﬁc genes affected by knock-
down of nuclear CRNDE transcripts, there appears to be potential for
both positive and negative feedback on upstream signaling molecules,
in addition to the likelihood that CRNDE mediates a subset of insulin/
IGF's downstream effects. Just as the PI3K/MAPK-activating mutations
in HCT116 presumably limit the ability of the signaling pathways to
be upregulated in response to insulin treatment (Section 4.1), their
presence is equally likely to limit the extent to which these pathways
can be attenuated through negative feedback by CRNDE. Curiously,
the precise upstream position within insulin/IGF signaling cascades at
which CRNDE exerts its feedback appears to depend on the mutation
status of the cell, as there were differences in the speciﬁc insulin
pathway-associated genes affected by CRNDE knockdown in ﬁbroblasts
(Table S2) and CRC cells.
CRNDE transcripts containing intronic segments, such as the gVC-
In4 region, are conﬁned to the nucleus, and we demonstrate that
these transcripts are controlled by insulin/IGF. lncRNAs have been
shown to act at multiple levels in regulating gene expression, includ-
ing epigenetic chromatin modiﬁcation, transcription, alternative
splicing, and translation. We are currently investigating the various
mechanisms through which CRNDE nuclear transcripts may mediate
insulin/IGF signaling and regulate central metabolism. Even though
CRNDE affected the alternative splicing of several genes, most of its
regulated transcriptomic changes are related to overall gene expres-
sion levels. CRNDE transcripts have previously been shown to interact
with the chromatin-modifying complexes PRC2 and CoREST in the nu-
cleus [4], thereby presumably repressing target gene expression via
histone methylation. Chromatin-based studies will be instrumental for
characterizing potential downstream epigenomic impacts of CRNDE
expression, including PRC2- and CoREST-mediated histonemethylation
of CRNDE's target genes, and the correlated transcriptional changes.
CRNDE's upregulation in cancer and the high sequence conservation
of the gVC-In4 region, recognizable even in the zebraﬁsh ortholog of
the CRNDE locus, both point to the importance of understanding its
normal function, especially in a developmental context.
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